13314-85-7Relevant articles and documents
Electrochemical-kinetic study of the oxidative cyclization of 2,5-dihydroxyphenylalanine, 2,5-dihydroxyphenylethylamine, and α-methyl-2,5-dihydroxyphenylethylamine
Young,Beidler
, p. 4833 - 4838 (1984)
-
VEGFR TYROSINE KINASE INHIBITORS
-
Page/Page column 36, (2014/12/12)
Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.
Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death
Robinson, Michael W.,Overmeyer, Jean H.,Young, Ashley M.,Erhardt, Paul W.,Maltese, William A.
experimental part, p. 1940 - 1956 (2012/05/20)
Methuosis is a novel caspase-independent form of cell death in which massive accumulation of vacuoles derived from macropinosomes ultimately causes cells to detach from the substratum and rupture. We recently described a chalcone-like compound, 3-(2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1- one (i.e., MIPP), which can induce methuosis in glioblastoma and other types of cancer cells. Herein, we describe the synthesis and structure-activity relationships of a directed library of related compounds, providing insights into the contributions of the two aryl ring systems and highlighting a potent derivative, 3-(5-methoxy, 2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one (i.e., MOMIPP) that can induce methuosis at low micromolar concentrations. We have also generated biologically active azide derivatives that may be useful for future studies aimed at identifying the protein targets of MOMIPP by photoaffinity labeling techniques. The potential significance of these studies is underscored by the finding that MOMIPP effectively reduces the growth and viability of Temozolomide-resistant glioblastoma and doxorubicin-resistant breast cancer cells. Thus, it may serve as a prototype for drugs that could be used to trigger death by methuosis in cancers that are resistant to conventional forms of cell death (e.g., apoptosis).
